Neurocrine Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Neurocrine Biosciences has a total shareholder equity of $2.7B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $3.5B and $816.1M respectively. Neurocrine Biosciences's EBIT is $602.3M making its interest coverage ratio -6.9. It has cash and short-term investments of $1.2B.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | -6.9x |
| Cash | US$1.23b |
| Equity | US$2.72b |
| Total liabilities | US$816.10m |
| Total assets | US$3.54b |
Recent financial health updates
Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly
Jul 28
Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly
Mar 31Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt
Dec 11Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?
Sep 12We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease
Jun 08Recent updates
Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)
Oct 10The Play On Neurocrine Biosciences
Oct 02Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data
Aug 28Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly
Jul 28Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth
Jul 09Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality
May 08Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings
Apr 27Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
Apr 25Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly
Mar 31Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside
Feb 11Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings
Jan 07Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt
Dec 11Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?
Sep 12We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease
Jun 08Financial Position Analysis
Short Term Liabilities: NBIX's short term assets ($1.9B) exceed its short term liabilities ($429.7M).
Long Term Liabilities: NBIX's short term assets ($1.9B) exceed its long term liabilities ($386.4M).
Debt to Equity History and Analysis
Debt Level: NBIX is debt free.
Reducing Debt: NBIX has no debt compared to 5 years ago when its debt to equity ratio was 70.2%.
Debt Coverage: NBIX has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: NBIX has no debt, therefore coverage of interest payments is not a concern.